Gilead Sciences to acquire Arcellx for $7.8 billion
Deal includes $115 per share cash payment plus $5 contingent on sales targets
Focus on anito-cel, a CAR-T therapy for multiple myeloma under FDA review
Expected to be accretive to earnings per share by 2028
📖 Full Retelling
Gilead Sciences announced on Monday it will acquire cancer therapy developer Arcellx for an implied equity value of $7.8 billion, expanding their cell therapy development collaboration that began in 2022. The Foster City, California-based biopharmaceutical company will pay $115 per share in cash at closing, representing a 79% premium to Arcellx's last closing price, with an additional $5 per share contingent upon achieving cumulative global net sales targets for their joint therapy anito-cel. Following the acquisition announcement, shares of Arcellx climbed 77.8% to $113.99 while Gilead fell approximately 1% in premarket trading, reflecting market reaction to the significant premium being paid. The acquisition centers on anito-cel, an experimental CAR-T therapy for multiple myeloma—a type of blood cancer—that Kite Pharma, a unit of Gilead Sciences, has been developing in partnership with Arcellx. CAR-T cell therapy represents an innovative cancer treatment approach that utilizes a patient's own genetically modified immune cells to locate and destroy cancer cells. The U.S. Food and Drug Administration is currently reviewing anito-cel, with a regulatory decision expected by December 23 of this year. Gilead has indicated that once the FDA approves anito-cel, the proposed transaction is expected to become accretive to earnings per share in 2028 and beyond, demonstrating their long-term confidence in the therapeutic potential of the collaboration.
🏷️ Themes
Biopharmaceutical M&A, Cancer Therapy Development, CAR-T Technology
Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir....
# Food and Drug Administration (FDA)
The **Food and Drug Administration (FDA)** is a federal agency within the **United States Department of Health and Human Services (HHS)**. It serves as the primary regulatory body responsible for protecting and promoting public health in the United States.
### ...
Gilead's acquisition of Arcellx expands its cell‑therapy portfolio and positions it to capture a share of the growing CAR‑T market, potentially boosting long‑term earnings.
Context & Background
Gilead has been expanding its oncology pipeline through acquisitions and partnerships
Arcellx is developing anito‑cel, a CAR‑T therapy for multiple myeloma, currently under FDA review
The deal values Arcellx at $7.8 billion, a 79% premium over its recent share price
The transaction includes a milestone payment tied to $6B in global net sales of anito‑cel by 2029
What Happens Next
The acquisition will close once regulatory approvals are obtained, after which Gilead will integrate Arcellx’s technology and pursue FDA approval of anito‑cel. Successful approval and sales milestones could make the deal accretive to Gilead’s earnings from 2028 onward.
Frequently Asked Questions
What is the purchase price per share?
$115 cash per share.
What are the milestone payments?
$5 per share contingent on $6B net sales of anito‑cel by 2029.
When is FDA expected to decide on anito‑cel?
By December 23 this year.
How will this affect Gilead’s earnings?
Expected to be accretive to EPS in 2028 and thereafter.
